UNSPSC 51112404: Procarbazine

This classification denotes a triazene compound with the molecular formula C12H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35S93Y190K, chemically known as p-toluamide, n-isopropyl-.alpha.- (2-methylhydrazino)-, monohydrochloride but more generally known as procarbazine, which bears US NIH Compound Identifier 4915. European Medicines Agency schedules Procarbazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10057MIG.

UNSPSC 51112404 Procarbazine is a Commodity code that captures pharmaceutical procurement activity in state and local health programs, though recent opportunities tagged to this code show minimal direct engagement with procarbazine as a named product line. Instead, state and local buyers using this code are pursuing broader pharmacy benefit management and drug distribution strategies, including direct-to-manufacturer prescription models and alternate contracting arrangements outside traditional pharmacy benefit managers and group purchasing organizations. The issuing bodies soliciting under this code include state health and human services agencies managing pharmacy benefits for employee health plans and Medicaid-eligible populations. Procurement mechanisms range from exploratory requests for information to formal competitive solicitations, and the work encompasses vendor capabilities assessment, contracting model development, and pricing negotiation for pharmaceutical access and fulfillment.

Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor information on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI targets vendors with experience in direct contracting for self-insured employers and government health plans within the past two years, negotiated net pricing models without rebates, and value-based or outcomes-based agreement capability. The state indicated this RFI is a preliminary information-gathering phase designed to inform future formal competitive solicitation strategy and program design before issuing a full RFP with financial and temporal parameters. No award values, budget ranges, set-asides, or incumbent contractor information were identified in the RFI materials. Geographic activity under this code appears concentrated in Texas based on recent filings, though the exploratory nature of the RFI suggests potential for expansion across state health systems pursuing alternative pharmaceutical distribution and pricing models.